WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Jeremiah Manele elected as Solomon Islands' new PM: Governor GeneralChina's trade with other BRICS members up 11.3 pct in Q1Rwanda's rebirthUS student protests continue, with over 270 arrests on weekendWisconsin tries to regain supremacy in the trenches under its 4th OUS stocks close mixed as traders digest Fed chair's messageWest Indies cricketer Devon Thomas banned for 5 years for match fixingChina to send Spain new giant panda couple on April 29A North Carolina man is charged with mailing an antisemitic threat to a Georgia rabbiChinese vice president meets Argentine foreign minister